Bharat,
Good points about Novastan already in use in Japan, thus reducing chances of "surprises" along the road to FDA approval. I am curious how well this drug is selling in Japan, as we could probably generalize this data to the US market.
I am still a bit skeptical, as I am am an ER nurse in a small rural hospital, and have never seen a case of Heparin induced thrombocytopenia, or heparin allergy.
I do believe, however, that if the AMI trials (using novastan and tPA together) are positive, we could be in for some great sales.
Ps, our hospital record for tPA (door to drug) is 8 minutes....and that was without pre-hospital (paramedic) involvement.
SO, any data on the Japaneese market, would be greatly appreciated, as I have yet to find any,
Mike |
